
Cahill Represents Financing Sources in Acquisition of Bausch & Lomb by Valeant Pharmaceuticals

Date: 08/06/13

Cahill represented the financing sources in each of Valeant's Common Stock, Bank Loan and High Yield Bond Transactions relating to its acquisition of Bausch & Lomb.

Cahill represented the underwriters in connection with the public offering of 27 million shares of common stock of Valeant Pharmaceuticals International, resulting in gross proceeds of approximately \$2.3 billion. Cahill also represented the initial purchasers in the offering of approximately \$3.2 billion aggregate principal amount of senior unsecured notes by Valeant and the lead arrangers in connection with approximately \$4.0 billion of new incremental term loan borrowings for Valeant, all in connection with financing Valeant's acquisition of Bausch & Lomb.

Attorneys

- William M. Hartnett
- Timothy B. Howell
- Noah B. Newitz
- Josiah M. Slotnick
- Patrick Gordon